Cancer drug prices in India are set to change from November 9, 2026, following a government decision to limit trade margins on 137 anti-cancer medicines. The move aims to make cancer treatment more affordable and reduce the financial burden on patients and their families. Prices of some medicines could fall by as much as 70%, although the actual reduction will depend on the medicine and its brand.
The National Pharmaceutical Pricing Authority (NPPA), operating under the Ministry of Chemicals and Fertilizers, has introduced a 30% cap on trade margins for 137 non-scheduled anti-cancer medicines. The measure is intended to prevent excessive margins across the supply chain and improve the affordability of essential cancer drugs.
The revised prices will take effect on November 9, 2026. Pharmaceutical manufacturers must notify the NPPA of the updated prices and revise their price lists in accordance with the new order. Hospitals and pharmacies will also be required to charge patients according to the revised pricing rules.
Which Cancer Medicines Are Covered
The list includes several non-scheduled anti-cancer medicines used to treat different types of cancer and related medical conditions. Some of the medicines covered by the measure are Pembrolizumab, Durvalumab, Osimertinib, Bevacizumab, Pegfilgrastim and Denosumab.
The extent of the price reduction will vary depending on the individual medicine and brand. While some products could see substantial reductions, the potential decrease of up to 70% should not be interpreted as a uniform price cut across all 137 medicines.
How Can Patients Check the New Prices
Patients and their families can check the revised prices through the government's Pharma Sahi Daam mobile application or the official NPPA website. These resources can help consumers identify updated medicine prices and understand the changes applicable to particular brands.
Patients are advised to verify the price of their prescribed medicines after the new rates come into effect. Checking the specific brand and formulation is important because the revised prices may differ across products.
Earlier Government Action on Cancer Drug Prices
The latest decision follows an earlier NPPA initiative introduced in 2019. At that time, the authority imposed a 30% ceiling on trade margins for 42 anti-cancer medicines.
According to the provided information, that measure resulted in price reductions of up to 90% across 526 medicine brands. The new order extends the trade-margin control approach to another group of 137 non-scheduled anti-cancer medicines.
The November 9, 2026, implementation date will mark the start of the latest pricing changes. The government expects the measure to help ease the cost of cancer treatment, while patients will need to check individual medicine prices to determine the actual savings.
